With £1,000, I’d buy 45 shares of this unloved dividend stock for a passive income boost

Despite falling vaccine sales, Stephen Wright thinks there’s a great passive income opportunity with Pfizer shares below pre-pandemic levels.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s fair to say the stock market has gone off Pfizer (NYSE:PFE) shares. But I think this could be a great stock to consider for investors looking to generate passive income.

Created with Highcharts 11.4.3Pfizer PriceZoom1M3M6MYTD1Y5Y10YALL25 Feb 201925 Feb 2024Zoom ▾Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '242020202020212021202220222023202320242024www.fool.co.uk

The stock is now trading 24% below its pre-pandemic levels. But while the company’s fortunes have waned, the 6% dividend yield looks like an opportunity to me.

Vaccine demand

Falling demand for Covid-19 vaccines is a big part of the reason the Pfizer share price has fallen. The firm is expecting only around 24% of the US population to receive boosters this year.

Should you invest £1,000 in Pfizer Inc. right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Pfizer Inc. made the list?

See the 6 stocks

Obviously, that’s a significant decline. And the impact hasn’t just been in terms of lower revenues, but also non-cash charges for product write-offs affecting the company’s bottom line. 

The question for investors, though, is whether the business is really worth less than it was before the start of the pandemic. I don’t think this is the case.

Demand for Covid-19 vaccines might have fallen, but Pfizer has been investing its windfall for the long term. This includes the acquisitions of Seagen to boost its future pipeline.

Earnings outlook

Without deep specialist knowledge, assessing precisely the prospects of a big pharmaceutical company is difficult-to-impossible. And this is a risk investors should consider.

Arguably, though, when shares trade well below what they’re worth, a precise assessment isn’t necessary. A stock selling for £10 is clearly cheap whether its intrinsic value is £30 or £35.

I think this might be the case with Pfizer. At the moment, the share price is around $27, but the most conservative estimates forecast earnings of $2.22 this year, rising to $3.04 by 2027.

That implies a price-to-earnings (P/E) ratio of around 12 this year, falling to nine within three years. And there’s another reason to be optimistic about the company’s prospects.

Size and strength

A common argument against investing in big pharmaceutical firms is their size makes it hard to generate meaningful growth. There’s some truth to this, but size also has its advantages.

In other sectors, larger companies with bigger balance sheets seem to be using their size to their advantage. This has been the case in both technology and energy.

Microsoft, Alphabet, Meta, and Nvidia have been dominating the AI space and ExxonMobil and Chevron have been expanding aggressively in oil. And a lot of this has been via acquisitions.

This illustrates the advantage of size and scale. And with healthcare, I think Pfizer has a similar advantage at a P/E ratio that looks like a bargain compared to the big tech and energy stocks.

A buying opportunity?

I think Pfizer shares look like a great long-term opportunity. It looks to me as though there’s a real chance the stock market is overlooking the company’s medium-term earnings potential.

Without a more thorough specialist assessment, I wouldn’t go all-in on the stock. But I think investing £1,000 to add 45 shares to my investment portfolio could be a really good move.

I’m not anticipating huge forward growth from a $155bn company. At today’s prices, though, I don’t think it needs it and I expect Pfizer’s size to help it maintain its position for some time.

Should you buy Pfizer Inc. now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has recommended Alphabet, Meta Platforms, Microsoft, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Investing Articles

How much do investors need in an ISA to earn a £2,500 monthly passive income?

Charlie Carman explores how investors could strive for £30k in tax-free passive income each year from a dividend stock portfolio.

Read more »

Investing Articles

How much would a 45-year-old need to invest in an ISA to earn a £1k monthly passive income at 65?

Harvey Jones looks at how much an investor would need to put away every month to build a steady passive…

Read more »

Investing Articles

3 things to do ahead of the new 2025-26 ISA year

It's time for us all to put on our investing boots and get to work on developing our plans for…

Read more »

Older couple walking in park
Investing Articles

Is £150,000 enough to generate £1,000 a month in passive income?

Stephen Wright takes a look at three UK stocks with dividend yields above 8% that passive income investors might be…

Read more »

Investing Articles

Aim to earn a £50k second income in retirement by investing just this much each month

Even with a small monthly investment, it’s possible to earn a £50k second income with a successful investment strategy and…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Down 22% in a month! Is this my chance to buy shares in this FTSE 100 outperformer?

Shares in InterContinental Hotels Group have outperformed the FTSE 100 over the long term. So is a chance to buy…

Read more »

Investing Articles

How much would Tesla stock be worth if it was valued like Nvidia?

The market seems to view Tesla as a tech stock rather than a car manufacturer. What could this mean for…

Read more »

Investing Articles

This ex-penny stock skyrocketed 900% in 2020! Is it about to surge again?

This subdued hydrogen penny stock was hot in 2020, but with demand for green hydrogen rising in Europe, can the…

Read more »